


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT  
Attorney Docket No.: 02307O-121000US  
Client Reference No.: 2001-512



By: Claudia Chang

RECEIVED  
MAY 24 2002  
TECH CENTER 1600/2900

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

GERSHWIN et al.

Application No.: 10/052,788

Filed: November 8, 2001

For: EPSILON IMMUNOGLOBULIN CHAIN DERIVED PEPTIDES FOR INDUCTION OF ANTI-IgE ANTIBODIES

Examiner: Not yet assigned

Art Unit: 1641

**INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.97 and §1.98**

Assistant Commissioner for Patents  
Washington, D.C. 20231


Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,  
  
Kevin Bastian  
Reg. No. 34,774

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8<sup>th</sup> Floor  
San Francisco, California 94111-3834  
Tel: 415-576-0200  
Fax: 415-576-0300  
KLB:clc

SF 1345901 v1

Please type a plus sign (+) inside this box → +

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>MAY 23 2002</i> <small>(use as many sheets as necessary)</small>				Application Number	10/052,788
				Filing Date	November 8, 2001
				First Named Inventor	Gershwin, Laurel J.
				Group Art Unit	1641
				Examiner Name	Not yet assigned
				Attorney Docket Number	023070-121000US
Sheet 15		of 1	RECEIVED MAY 24 2002 1600/2900 TECH CENTER		

U.S. PATENT DOCUMENTS					
Examiner Initials *	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code <sup>2</sup> (if known)		
AA		5,583,005		Nishimura et al.	12-10-1996
AB		5,629,415		Hollis et al.	05-13-1997

FOREIGN PATENT DOCUMENTS						
Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)		

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS						
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				
	AC	HALLIWELL and HINES, "Studies on equine recurrent uveitis. I: Levels of immunoglobulin and albumin in the aqueous humor of horses with and without intraocular disease", <i>Current Eye Research</i> , 4:1023-1031 (1985)				
	AD	MARTI, E. et al., "Partial sequence of the equine immunoglobulin epsilon heavy chain cDNA" <i>Journal of Veterinary Immunology and Immunopathology</i> , 47:363-367 (1995)				
	AE	MARTI, E. et al., "Chicken antibodies to a recombinant fragment of the equine immunoglobulin epsilon heavy-chain recognising native horse IgE," <i>Veterinary Immunology and Immunopathology</i> , 59:253-270 (1997)				
	AF	NAVARRO, P. et al., "The Complete cDNA and Deduced Amino Acid Sequence of Equine IgE," <i>Journal of Molecular Immunology</i> , 32:1-8 (1995)				
	AG	WATSON, J.L. et al., "Isolation and Partial Expression of a cDNA Clone Encoding Equine IgE Heavy Chain and Production of Polyclonal Antibodies to the Recombinant Protein," <i>Veterinary Allergy and Clinical Immunology</i> , 5:135-142 (1997)				
	AH	WATSON, J.L. et al., "Phenotypic Characterization of Lymphocyte Subpopulations in Horses Affected with Chronic Obstructive Pulmonary Disease and in Normal Controls," <i>Vet. Pathol.</i> 34:108-116 (1997)				
	AI	GRIOT-WENK, M.E. et al., "Partial sequences of feline and caprine immunoglobulin epsilon heavy chain cDNA and comparative binding studies of recombinant IgE fragment-specific antibodies across different species," <i>Journal of Veterinary Immunology and Immunopathology</i> , 75:59-69 (2000)				

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

SF 1345901 v1